Grant: Master's Award: Canada Graduate Scholarships
University of Saskatchewan
$17,500.00
Analysis of a novel combination therapy of small RNAs for Hepatitis C virus
EF 2014-15
Résumé
Hepatitis C virus (HCV) infects approximately 170 million people worldwide and is a major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV relies on a small liver-specific molecule called miR-122 to establish a productive infection. A therapeutic, Antagomir, has been designed to bind and inactivate miR-122, thus destabilizing HCV and reducing viral replication in patients. This therapeutic is promising however there is concern regarding its long term use since miR-122 may also inhibit cancer development. My masters research aims to enhance the effectiveness of this therapeutic by introducing a second molecule, siRNA, which will work synergistically when in combination with Antagomir. Combination treatment will allow less Antagomir to be used and reduce the likelihood of adverse side effects. siRNA works to decrease viral replication by specifically binding and cleaving the conserved region of the HCV genome where miR-122 binds. Our preliminary data shows these two strategies work synergistically in cultured human hepatocytes. A portion of my research will be to verify the therapeutic potential of the combination treatment in a mouse model. There also appears to be an alternate mechanism by which the siRNAs inhibit viral inhibition by interfering with the activity of miR-122. I will also explore the alternative mechanism of inhibition further in hopes of designing better HCV inhibitors that exploits this mechanism.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331350
Name
Schinold Michael J
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Analysis of a novel combination therapy of small RNAs for Hepatitis C virus
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Hepatitis C Virus; Locked Nucleic Acid; Mir122; Sirna; Synergy; Therapy; Viral Host Interaction
Abstract
Hepatitis C virus (HCV) infects approximately 170 million people worldwide and is a major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV relies on a small liver-specific molecule called miR-122 to establish a productive infection. A therapeutic, Antagomir, has been designed to bind and inactivate miR-122, thus destabilizing HCV and reducing viral replication in patients. This therapeutic is promising however there is concern regarding its long term use since miR-122 may also inhibit cancer development. My masters research aims to enhance the effectiveness of this therapeutic by introducing a second molecule, siRNA, which will work synergistically when in combination with Antagomir. Combination treatment will allow less Antagomir to be used and reduce the likelihood of adverse side effects. siRNA works to decrease viral replication by specifically binding and cleaving the conserved region of the HCV genome where miR-122 binds. Our preliminary data shows these two strategies work synergistically in cultured human hepatocytes. A portion of my research will be to verify the therapeutic potential of the combination treatment in a mouse model. There also appears to be an alternate mechanism by which the siRNAs inhibit viral inhibition by interfering with the activity of miR-122. I will also explore the alternative mechanism of inhibition further in hopes of designing better HCV inhibitors that exploits this mechanism.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schinold, Michael J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~